OSE Pharma

Boehringer Ingelheim

Research

ASCO: BI, OSE report promising early results for I-O drug

BI and OSE unveiled data from a phase 1 trial of BI 765063, a SIRP-alpha inhibitor, reporting that 45% of evaluable patients benefited.

Arlene Weintraub May 21, 2021 10:05am

cancer newspaper

OSE details strategy targeting 'don't eat me' signal in cancer

Nov 16, 2020 8:53am

MSKs Prasad Adusumilli

OSE, MSK ally to advance anti-CD127 NSCLC candidate

Jun 13, 2017 5:51am